Abstract:Podocyte foot process (FP) is dysregulated in nephrotic syndrome. The effacement of podocyte FPs typically arises following perturbations in the actin cytoskeleton. Recent data suggest that the effects of calcineurin (CaN) inhibitor cyclosporine A (CsA) are independent of its effects on T-cells, and CsA has been identified as stabilizing the actin cytoskeleton through stabilizing synaptopodin in podocytes, and thereby directly reducing proteinuria. Other studies showed that CsA could regulate cofilin-1 directly within tubular epithelial cells. However, whether synaptopodin is the only target of CsA or whether the antiproteinuric role of CsA is played by regulating cofilin-1 in podocytes has not been studied. In the present study, changes in the expression and distribution of nephrin, synaptopodin, cofilin-1 and phosphorylated cofilin-1 (pho-cofilin-1) were detected in both puromycin aminonucleoside (PAN) induced nephrotic rats treated with CsA and cultured podocytes exposed to PAN with/without CsA. Cofilin-1, synaptopodin mRNA was knocked down or combined by siRNA to investigate whether cofilin-1 was critical for the protective effect of CsA and whether the effect of CsA on cofilin-1 was independent of its effect on synaptopodin. We found that CsA reduced proteinuria and repaired FP effacement of PAN-induced nephropathy, restored expression of nephrin, synaptopodin, cofilin-1, pho-cofilin-1 both in vivo and in vitro. CsA also repaired actin cytoskeleton impaired by PAN in vitro. The protective effect of CsA was diminished when cofilin-1 was knocked down compared to negative control. Synaptopodin knocked down had no effect on cofilin-1. The protective effect of CsA decreased significantly when cofilin-1 and synaptopodin were simultaneously knocked down compared to only cofilin-1 knock down. In conclusion, the antiproteinuric effect of CsA is derived from the stabilization of the podocyte actin cytoskeleton by upregulating expression of cofilin-1, which was independent of its effect on synaptopodin.

Targeting Extracellular Cyclophilin A via an Albumin‐Binding Cyclosporine A Analogue

Cyclosporin A-Based PROTACs Can Deplete Abundant Cellular Cyclophilin A without Suppressing T Cell Activation

Human Structural Proteome-Wide Characterization of Cyclosporine A Targets

Inhibition of Interleukin 4 Receptor Expression on Human Lymphoid Cells by Cyclosporin

Anti-Inflammatory Effects of A Cyclosporine Receptor-Binding Compound, D-43787

Cyclosporin A Impairs Dendritic Cell Migration by Regulating Chemokine Receptor Expression and Inhibiting Cyclooxygenase-2 Expression

Stephanthraniline A And Cyclosporine A Synergize To Inhibit T-Cell Response In Vitro And In Vivo

Cyclosporine A Regulates Influenza A Virus-induced Macrophages Polarization and Inflammatory Responses by Targeting Cyclophilin A

Preparation,Characterization and Pharmacokinetics of Long Circulated Liposome Encapsulated Cyclosproine

CHBP and Caspase-3 Sirna Protected Mouse TCMK-1 Cells Treated by Cyclosporine A Via Suppressing Caspase-3 and Apoptosis.

Cyclosporine-A induced cytotoxicity within HepG2 cells by inhibiting PXR mediated CYP3A4/CYP3A5/MRP2 pathway

Synthesis of biotinylated cyclosporin A and studies on its interaction with human cyclophilin A

Structural Basis for the Non-Immunosuppressive Character of the Cyclosporin A Analogue Debio 025

Comparative Pharmacokinetic Profile of Cyclosporine (csa) with a Decapeptide and a Linear Analogue.

Cyclosporin A inhibits creatine uptake by altering surface expression of the creatine transporter

Dual action of macrophage miR‐204 confines cyclosporine A‐induced atherosclerosis

Cyclosporine A protects podocytes via stabilization of cofilin-1 expression in the unphosphorylated state.

Structure-guided Manipulation of the Regioselectivity of the Cyclosporine A Hydroxylase CYP-sb21 from Sebekia Benihana

Domain Characterization of Cyclosporin Regio-Specific Hydroxylases in Rare Actinomycetes

Anti-CD3antibody-induced Expression Ofbothp55andp75chains Ofthehighaffinity Interleukin-2 Receptor on Humant Lymphocytes Isinhibited Bycyclosporin A

Nano-Sustained CO-Releasing Molecules Alleviates Cyclosporin-A-Induced Nephrotoxicity and Renal Fibrosis by Inhibiting NLRP3 Inflammasome-Mediated TGF-β/Smad Signaling Pathway